logo
Plus   Neg
Share
Email

Roche Announces First Approval For Tecentriq-based Therapy In China

Roche (RHHBY) said the China National Medical Products Administration has approved Tecentriq in combination with chemotherapy for the first-line treatment of patients with extensive-stage small cell lung cancer. The company noted that approval in China comes less than a year after the FDA and EMA approvals in the indication.

In January 2020, the China National Medical Products Administration also accepted the supplemental Biologics License Application for Tecentriq in combination with Avastin for the treatment of people with unresectable hepatocellular carcinoma.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Auto insurers Allstate Corp. as well as American Family Insurance announced their plans to return some of auto insurance premiums, totaling $800 million, to customers citing less driving as more people are staying home amid coronavirus or Covid-19 crisis. Allstate is providing a Shelter-in-Place Payback totaling more than $600 million. Samsung Electronics Co Ltd (SMSN.L, SSNNF.OB, SSNLF.OB) expects that its first-quarter operating profit will increase about 2.73 percent from last year, sales will also increase 4.98 percent. JPMorgan Chase CEO Jamie Dimon said it expects the bank's earnings to be "down meaningfully" in 2020 due to the disruptions created by coronavirus pandemic. He also noted that the U.S. was not adequately prepared for the pandemic. In his annual letter to the company's shareholders, Dimon said that the bank's board may consider suspending the dividend in an extremely adverse scenario.
Follow RTT
>